来自ICS/LABA的FF/UMEC/VI升级后喘患者的恶化减少:回顾性队列研究
Alan P Baptist1, Rosirene Paczkowski2, Guillaume Germain3
1Division of Allergy and Clinical Immunology, Henry Ford Health and MI State University Health Sciences, Detroit, MI, USA.
Pulmonary therapy
|October 28, 2025
概括
将喘治疗升级为流动松酸/尤克利迪尼/维兰特醇 (FF/UMEC/VI) 显著减少了恶化,住院和成本. 这种现实世界的证据支持FF/UMEC/VI对于在吸入性皮质类固醇/长效β-激动剂治疗中不受控制的患者.
科学领域:
- 肺部病理学 肺部病理学
- 现实世界的证据.
- 药物治疗 药物治疗
背景情况:
- 自2020年以来,美国的喘可以使用酸/乌米克利迪尼/维兰特罗尔 (FF/UMEC/VI).
- 关于FF/UMEC/VI的临床和经济益处的现实数据有限.
- 这项研究评估了FF/UMEC/VI在美国喘患者中之前接受ICS/LABA的有效性.
研究的目的:
- 评估FF/UMEC/VI在美国喘患者中的有效性.
- 评估减轻恶化,医疗保健利用率和成本的情况.
- 分析之前用吸入性皮质类固醇/长效β-激动剂 (ICS/LABA) 治疗的患者的结局.
主要方法:
- 使用行政索赔数据进行了回顾性,纵向的前后研究 (09/09/201912/31/2023).
- 包括在FF/UMEC/VI启动之前接受ICS/LABA的喘成年人.
- 评估了恶化,医疗保健资源的利用,口服皮质类固醇 (OCS) 和短效β-激动剂 (SABA) 的使用,以及启动前后的成本.
主要成果:
- FF/UMEC/VI的启动将恶化的概率降低了52%,中度至重度恶化的概率降低了38%.
- 与喘相关的住院病例减少了25%,口服皮质类固醇分发减少了36%,SABA使用减少了54%.
- 年均喘相关医疗费用减少了1115美元;在FF/UMEC/VI剂量之间,结果相似.
结论:
- 升级到FF/UMEC/VI与喘恶化和住院病例的显著减少有关.
- 治疗FF/UMEC/VI导致口服皮质类固醇和SABA使用减少.
- 将治疗升级到FF/UMEC/VI导致ICS/LABA不受控制的患者的喘相关医疗费用降低.
相关概念视频
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Asthma-IV: Nursing Management
3.7K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.7K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K


